Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vertex Pharmaceuticals

482.32
-9.3250-1.90%
Volume:428.67K
Turnover:208.78M
Market Cap:123.85B
PE:-231.88
High:491.62
Open:490.15
Low:479.78
Close:491.64
Loading ...

Vertex Pharmaceuticals files automatic mixed securities shelf

TIPRANKS
·
14 Feb

Vertex Pharmaceuticals Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
14 Feb

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
14 Feb

Vertex 9-Mos Net Y3.01B Vs Net Y2.56B

Dow Jones
·
13 Feb

Vertex Pharmaceuticals: Strong Financial Performance and Promising Future Prospects Reinforce Buy Rating

TIPRANKS
·
13 Feb

Cautious Outlook on Vertex Pharmaceuticals: Hold Rating Amid Growth Concerns and Premium Valuation

TIPRANKS
·
13 Feb

CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates

Zacks
·
12 Feb

Vertex Pharmaceuticals Raised to Hold From Sell by Canaccord Genuity

Dow Jones
·
12 Feb

Daiwa Adjusts Price Target on Vertex Pharmaceuticals to $530 From $550, Maintains Buy Rating

MT Newswires Live
·
12 Feb

Vertex Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
12 Feb

U.S. RESEARCH ROUNDUP-Edison International, Onestream, Vertex Pharmaceuticals

Reuters
·
12 Feb

Vertex Pharmaceuticals Inc : Leerink Partners Raises Target Price to $550 From $542

THOMSON REUTERS
·
12 Feb

Vertex Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
12 Feb

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
12 Feb

Vertex Pharmaceuticals upgraded to Hold from Sell at Canaccord

TIPRANKS
·
12 Feb

BUZZ-Vertex falls after Q4 profit, sales of gene therapy disappoint

Reuters
·
12 Feb